Type in a keyword and see the report right away. Explore your online world!
If you have already a Newsmeter account:
You can free sign up for Newsmeter:
x
Axoltis’ drug, NX210c, failed to meet clinical endpoints in a Phase II trial – but the company says other readouts are positive.
Moving drugs to patient without routing every transaction through a pharmacy benefit manager (PBM) appears simple in concept. However, in practice, it creates two very different pricing and contracting problems, according to Matthew Fornataro, partner at Arnold & Porter, and Alana Reid, senior associate at the firm.
1. Editorial Contributions 2. Video Features 3. Sponsored Content Programs 4. Event Speaking Opportunities How...
Biopharma C-suite expects dealmaking to rebound as capital access remains a top challenge.
Monthly insights, guidance alerts and blogs from global life sciences law firms, compiled for you in one place.
To celebrate the spooky season, we reflect on the ghosts, ghouls, and growth in biotech this past year.
The collaboration will integrate AI more directly into scientific instrumentation, with the aim of closing the gap between computational predictions and experimental validation.
Stryker is pouring roughly $400 million into CMR Surgical, with an option to buy the robotics firm outright and sell its tech across the US.
Conference Chair Adam Mostafa on why finance has become strategy for clinical-stage biotech.
The sale brings the company's combined voucher proceeds to $413 million, following the approval of two gene therapies within the same number of months.
UK-based OMass Therapeutics has closed an oversubscribed $310 million Series C round to drive its endocrinology and immunology pipeline toward the clinic.
Sponsors trialing drugs in the European Union (EU) will be able to continue seeking input from the European Medicines Agency (EMA) after the regulator confirmed it would turn a pilot EU-level advice program into a permanent initiative.
Shweta Maniar is the Global Director of Life Sciences Solutions and Strategy for Google Cloud,...
How wielding agentic AI can be used as a powerful tool, from navigating the lab to regulatory reviews.
Experts discuss how current US pricing policy is reshaping decisions about when, where, and how to launch therapies around the world.
